N/A N=12 Randomized Single-blind Treatment

NB-UVB Phototherapy With and Without Topical LCD Treatment: a Bilateral Pilot Study

Plaque Psoriasis

Bottom Line

View on ClinicalTrials.gov: NCT00708851 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Apr 2015

Primary outcome: Primary: The Difference in Bilateral Static Physician's Global Assessment (sPGA) Scores, and Erythema, Scaling, and Induration (ESI) Scores of Bilateral Target Lesion Scores Across Visits for Each Condition and Between Conditions. — 77.8; 85.4; 88.5; 88.9 percent improvement from baseline

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: LCD Solution with NB-UVB Phototherapy (Other); NB-UVB Light Device (311-315 nm) (Device)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: NeoStrata Company, Inc.
Primary completion: Jan 2008

Outcome Measures

Outcome	Result	p-value
PRIMARY The Difference in Bilateral Static Physician's Global Assessment (sPGA) Scores, and Erythema, Scaling, and Induration (ESI) Scores of Bilateral Target Lesion Scores Across Visits for Each Condition and Between Conditions.	77.8; 85.4; 88.5; 88.9; 84.2; 85.7	—
SECONDARY The Difference in Number and Severity of Treatment-related Adverse Reactions Between Conditions.	3; 3	—

Summary

The purpose of this study is to determine if combining a daily at-home regimen using an LCD Solution with a 3 times weekly outpatient narrowband UVB phototherapy regimen could be a safe, effective, rapid, and, convenient treatment for plaque psoriasis.

Eligibility Criteria

Inclusion Criteria

18 years old or older
able and willing to provide written informed consent
symmetrical plaque psoriasis
able and willing to attend phototherapy sessions and apply LCD at home
negative pregnancy test for women of child-bearing potential

Exclusion Criteria

current or recent other treatments for psoriasis
hypersensitivity to LCD or UVB light
current or previous skin cancer
pregnant or nursing mother
participating in another clinical trial

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00708851). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.